Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem Buys Biomol International for $18M

NEW YORK (GenomeWeb News) – Enzo Biochem said today that it has acquired the US assets and stock of the two UK subsidiaries of Biomol International for $18 million in cash and stock, plus earn-outs over the next two years.
 
Privately held Biomol sells enzymes, peptides, substrates, and antibodies for signal transduction, lipid research, apoptosis, neuroscience and drug discovery, with a research focus on the functional proteomics field. The firm has annual revenues of roughly $11.5 million with 9 percent annual growth, according to New York-based Enzo.
 
“Coupling Biomol with our acquisition of Axxora Life Sciences less than a year ago, we have succeeded in transforming Enzo Life Sciences into a global manufacturer and marketer of reagents and systems spanning a wide spectrum of scientific applications,” Barry Weiner, president of Enzo, said in a statement.
 
Biomol has 50 employees in the US and UK. Enzo did not say whether they would all join the firm’s operations. However, it said that Biomol’s senior management and founders would remain “actively involved” with Enzo.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.